EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products

Ka Iong Chan, Siyuan Zhang, Guodong Li, Yida Xu, Liao Cui, Yitao Wang, Huanxing Su, Wen Tan, Zhangfeng Zhong

Aging and disease · 2024

DOI: 10.14336/ad.2023.0520 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Aging and disease, 2024. Verfasst von Ka Iong Chan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Med…. Hauptthemen laut MEDLINE: Biological Products, Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 590 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Various diseases, including cancers, age-associated disorders, and acute liver failure, have been linked to the oncogene, MYC. Animal testing and clinical trials have shown that sustained tumor volume reduction can be achieved when MYC is inactivated, and different combinations of therapeutic agents including MYC inhibitors are currently being developed. In this review, we first provide a summary of the multiple biological functions of the MYC oncoprotein in cancer treatment, highlighting that the equilibrium points of the MYC/MAX, MIZ1/MYC/MAX, and MAD (MNT)/MAX complexes have further potential in cancer treatment that could be used to restrain MYC oncogene expression and its functions in tumorigenesis. We also discuss the multifunctional capacity of MYC in various cellular cancer processes, including its influences on immune response, metabolism, cell cycle, apoptosis, autophagy, pyroptosis, metastasis, angiogenesis, multidrug resistance, and intestinal flora. Moreover, we summarize the MYC therapy patent landscape and emphasize the potential of MYC as a druggable target, using herbal medicine modulators. Finally, we describe pending challenges and future perspectives in biomedical research, involving the development of therapeutic approaches to modulate MYC or its targeted genes. Patients with cancers driven by MYC signaling may benefit from therapies targeting these pathways, which could delay cancerous growth and recover antitumor immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsNeoplasmsAnimalsHumansGenes, mycProto-Oncogene Proteins c-mycRepressor ProteinsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsSignal Transduction

Substanzen

Proto-Oncogene Proteins c-mycRepressor ProteinsBiological ProductsBasic Helix-Loop-Helix Leucine Zipper Transcription Factors

Autor:innen und Institutionen

  • Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China.
  • Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Zhanjiang 524000, China.
  • School of Pharmacy, Lanzhou University, Lanzhou 730000, China.

Zitieren

APA

Chan, K. I., Zhang, S., Li, G., Xu, Y., Cui, L., Wang, Y., Su, H., Tan, W., & Zhong, Z. (2024). MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products. Aging and disease. https://doi.org/10.14336/ad.2023.0520

Vancouver

Chan KI, Zhang S, Li G, Xu Y, Cui L, Wang Y, et al. MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products. Aging and disease. 2024. doi:10.14336/ad.2023.0520

BibTeX
@article{Chan2024,
  author = {Chan, Ka Iong and Zhang, Siyuan and Li, Guodong and Xu, Yida and Cui, Liao and Wang, Yitao and Su, Huanxing and Tan, Wen and Zhong, Zhangfeng},
  title = {MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products},
  journal = {Aging and disease},
  year = {2024},
  doi = {10.14336/ad.2023.0520}
}
Kostenlos starten →